CO6640306A2 - Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso - Google Patents
Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su usoInfo
- Publication number
- CO6640306A2 CO6640306A2 CO12223245A CO12223245A CO6640306A2 CO 6640306 A2 CO6640306 A2 CO 6640306A2 CO 12223245 A CO12223245 A CO 12223245A CO 12223245 A CO12223245 A CO 12223245A CO 6640306 A2 CO6640306 A2 CO 6640306A2
- Authority
- CO
- Colombia
- Prior art keywords
- angiotensin
- combination
- receptor antagonists
- xanthine oxidase
- oxidase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una combinación de principios activos, a saber de un inhibidor de xantina oxidasa con uno o más antagonistas del receptor de angiotensina II, composiciones farmacéuticas que contienen a dichos principios activos, para uso en el tratamiento terapéutico humano o veterinario; y métodos para su preparación.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2010A000232A IT1400311B1 (it) | 2010-05-10 | 2010-05-10 | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6640306A2 true CO6640306A2 (es) | 2013-03-22 |
Family
ID=42753377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12223245A CO6640306A2 (es) | 2010-05-10 | 2012-12-10 | Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso |
Country Status (23)
Country | Link |
---|---|
US (1) | US20130131128A1 (es) |
EP (1) | EP2568982B1 (es) |
JP (1) | JP2013526503A (es) |
KR (1) | KR20130101447A (es) |
CN (1) | CN103037861A (es) |
AR (1) | AR081376A1 (es) |
AU (1) | AU2011252151A1 (es) |
BR (1) | BR112012028887A2 (es) |
CA (1) | CA2798573A1 (es) |
CL (1) | CL2012003143A1 (es) |
CO (1) | CO6640306A2 (es) |
EA (1) | EA201201528A1 (es) |
EC (2) | ECSP12012332A (es) |
IL (1) | IL222927A0 (es) |
IT (1) | IT1400311B1 (es) |
MA (1) | MA34297B1 (es) |
MX (1) | MX2012013054A (es) |
NZ (1) | NZ603414A (es) |
PE (1) | PE20130812A1 (es) |
SG (1) | SG185474A1 (es) |
TW (1) | TW201206432A (es) |
WO (1) | WO2011141431A1 (es) |
ZA (1) | ZA201209295B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3028371B1 (fr) * | 2014-11-06 | 2016-11-18 | Bull Sas | Procede de surveillance et de controle deportes d'un cluster utilisant un reseau de communication de type infiniband et programme d'ordinateur mettant en oeuvre ce procede |
KR102284764B1 (ko) | 2020-07-08 | 2021-08-04 | 주식회사 우드메탈 | 멀티빔구조를 통한 부속의 결속이 용이한 칸막이 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE142494T1 (de) | 1990-11-30 | 1996-09-15 | Teijin Ltd | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
IS1756B (is) | 1991-02-21 | 2000-12-28 | Sankyo Company Limited | Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða |
DE122010000013I1 (de) | 1998-06-19 | 2010-07-08 | Teijin Pharma Ltd | Polymorphe modifikationen der 2-(3-cyano-4-isobutylphenyl)-4-methyl-5-thiazol-carbonsäure und verfahren zu ihrer herstellung |
DE60119368T2 (de) | 2000-11-21 | 2007-05-03 | Sankyo Co., Ltd. | Zusammensetzung enthaltend einen angiotensin-ii-rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck |
US20040122067A1 (en) | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
NZ541454A (en) | 2003-01-31 | 2008-04-30 | Daiichi Sankyo Co Ltd | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
WO2005027887A2 (en) * | 2003-09-17 | 2005-03-31 | Cardimone Pharma Corporation | Methods and compositions for improving endothelial function |
EP1940397A4 (en) * | 2005-08-03 | 2010-01-20 | Takeda Pharmaceuticals North A | METHOD FOR TREATING HYPERTONIA |
EP1957064A4 (en) | 2005-11-21 | 2010-01-06 | Tap Pharmaceutical Prod Inc | TREATMENT OF QT INTERVAL EXTENSION AND RELEVANT DISEASES |
BRPI0718611A2 (pt) | 2006-11-13 | 2014-02-25 | Takeda Pharmaceuticals North America Inc | Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase. |
-
2010
- 2010-05-10 IT ITRM2010A000232A patent/IT1400311B1/it active
-
2011
- 2011-05-09 BR BR112012028887A patent/BR112012028887A2/pt not_active IP Right Cessation
- 2011-05-09 US US13/697,066 patent/US20130131128A1/en not_active Abandoned
- 2011-05-09 SG SG2012082319A patent/SG185474A1/en unknown
- 2011-05-09 JP JP2013509533A patent/JP2013526503A/ja not_active Abandoned
- 2011-05-09 CN CN2011800232573A patent/CN103037861A/zh active Pending
- 2011-05-09 EP EP11718734.4A patent/EP2568982B1/en not_active Not-in-force
- 2011-05-09 MX MX2012013054A patent/MX2012013054A/es not_active Application Discontinuation
- 2011-05-09 AR ARP110101590A patent/AR081376A1/es unknown
- 2011-05-09 MA MA35430A patent/MA34297B1/fr unknown
- 2011-05-09 EA EA201201528A patent/EA201201528A1/ru unknown
- 2011-05-09 PE PE2012002151A patent/PE20130812A1/es not_active Application Discontinuation
- 2011-05-09 NZ NZ603414A patent/NZ603414A/en not_active IP Right Cessation
- 2011-05-09 WO PCT/EP2011/057438 patent/WO2011141431A1/en active Application Filing
- 2011-05-09 CA CA2798573A patent/CA2798573A1/en not_active Abandoned
- 2011-05-09 AU AU2011252151A patent/AU2011252151A1/en not_active Abandoned
- 2011-05-09 KR KR1020127032188A patent/KR20130101447A/ko not_active Application Discontinuation
- 2011-05-09 TW TW100116119A patent/TW201206432A/zh unknown
-
2012
- 2012-11-08 CL CL2012003143A patent/CL2012003143A1/es unknown
- 2012-11-08 IL IL222927A patent/IL222927A0/en unknown
- 2012-12-07 ZA ZA2012/09295A patent/ZA201209295B/en unknown
- 2012-12-10 CO CO12223245A patent/CO6640306A2/es not_active Application Discontinuation
- 2012-12-10 EC ECSP12012332 patent/ECSP12012332A/es unknown
- 2012-12-10 EC ECSP12012331 patent/ECSP12012331A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20130131128A1 (en) | 2013-05-23 |
WO2011141431A1 (en) | 2011-11-17 |
PE20130812A1 (es) | 2013-08-08 |
AR081376A1 (es) | 2012-08-29 |
ECSP12012332A (es) | 2013-02-28 |
TW201206432A (en) | 2012-02-16 |
KR20130101447A (ko) | 2013-09-13 |
CL2012003143A1 (es) | 2013-06-21 |
AU2011252151A1 (en) | 2012-11-29 |
ZA201209295B (en) | 2013-08-28 |
NZ603414A (en) | 2014-03-28 |
BR112012028887A2 (pt) | 2016-07-26 |
EP2568982A1 (en) | 2013-03-20 |
MX2012013054A (es) | 2013-03-05 |
CA2798573A1 (en) | 2011-11-17 |
JP2013526503A (ja) | 2013-06-24 |
ECSP12012331A (es) | 2013-02-28 |
IL222927A0 (en) | 2012-12-31 |
IT1400311B1 (it) | 2013-05-24 |
SG185474A1 (en) | 2012-12-28 |
EA201201528A1 (ru) | 2013-04-30 |
EP2568982B1 (en) | 2014-04-02 |
MA34297B1 (fr) | 2013-06-01 |
CN103037861A (zh) | 2013-04-10 |
ITRM20100232A1 (it) | 2011-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015001984A1 (es) | (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos. | |
ECSP11011459A (es) | Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CL2013003547A1 (es) | Peptido derivado de oxintomodulina; polinucleotido que lo codifica; composicion farmaceutica que lo comprende; uso del peptido para tratar la obesidad. | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
CO6430456A2 (es) | Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
CO6400170A2 (es) | Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
PA8849701A1 (es) | Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico | |
CL2011000214A1 (es) | Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona. | |
CL2012002551A1 (es) | Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
MX2019008817A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma. | |
UY32520A (es) | Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides | |
CL2012001757A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas. | |
GB201014391D0 (en) | Drug composition and its use in therapy | |
CO6640306A2 (es) | Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso | |
CR20120617A (es) | Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso | |
BR112013004714A2 (pt) | "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos" | |
CR20120461A (es) | Hidrato del hidrobromuro de agomelatina y preparación de éste | |
CO6630144A2 (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso | |
CL2012000355A1 (es) | Compuestos derivados de 4-amino-butenamida; composicion farmaceutica; y uso en el tratamiento de la epoc. | |
TR201102857A2 (tr) | Telmisartan ve diüretik kombinasyonunun farmasötik formülasyonları. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |